Renaissance Capital logo

OKYO Pharma Priced, Nasdaq: OKYO

Preclinical biotech developing a lipidated chemerin peptide for dry eye disease.

Industry: Health Care

Latest Trade: $1.06 0.00 (0.0%)

First Day Return: -9.5%

Return from IPO: -73.5%

Industry: Health Care

We are a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate, for the treatment of dry-eye disease. We also plan to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical analogue candidate that is currently in developmental stage. OK-101, our lead preclinical product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as dry eye disease, or DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye.
more less
IPO Data
IPO File Date 03/04/2022
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 0.6
Deal Size ($mm) $3
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/16/2022
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 0.6
Deal Size ($mm) $3
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
ThinkEquity
Company Data
Headquarters London, United Kingdom
Founded 2007
Employees at IPO 2
Website www.okyopharma.com

OKYO Pharma (OKYO) Performance